Skip to main content

6 Result(s)

within Hidenori Mizugaki Remove this filter Medicine & Public Health Remove this filter Oncology Remove this filter Pharmacology/Toxicology Remove this filter

and

  1. No Access

    Article

    A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors

    Eg5, a mitotic motor kinesin protein, plays an essential role in bipolar spindle formation in the M phase of the cell cycle. LY2523355 (litronesib) is an allosteric inhibitor of Eg5. This phase 1 and dose-find...

    Hiroshi Wakui, Noboru Yamamoto, Satoru Kitazono… in Cancer Chemotherapy and Pharmacology (2014)

  2. No Access

    Article

    A phase I study of resminostat in Japanese patients with advanced solid tumors

    This study was performed to evaluate the safety and determine the recommended dose (RD) of resminostat monotherapy, an oral histone deacetylase (HDAC) inhibitor, in Japanese patients with advanced solid tumors.

    Satoru Kitazono, Yutaka Fujiwara, Shinji Nakamichi… in Cancer Chemotherapy and Pharmacology (2015)

  3. No Access

    Article

    Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors

    RO4987655 is an oral and selective inhibitor of MEK, a key enzyme of the mitogen-activated protein kinase (MAPK) signaling pathway. This phase I dose-escalation study of RO4987655 in Japanese patients with adv...

    Shinji Nakamichi, Hiroshi Nokihara, Noboru Yamamoto… in Investigational New Drugs (2015)

  4. Article

    Open Access

    Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer

    Background Ipilimumab is an antibody that targets the cytotoxic T-lymphocyte antigen-4 to potentiate an antitumor response. Adding ipilimumab 10 mg/kg to paclitaxel (PTX) and carboplatin ...

    Hidehito Horinouchi, Noboru Yamamoto, Yutaka Fujiwara… in Investigational New Drugs (2015)

    Download PDF (270 KB) View Article

  5. Article

    Open Access

    A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)

    Veliparib is a potent, orally bioavailable PARP inhibitor that enhances efficacy of DNA-damaging chemotherapeutic agents. The study objectives were to determine the recommended phase 2 dose (RPTD) of veliparib...

    Hidenori Mizugaki, Noboru Yamamoto… in Cancer Chemotherapy and Pharmacology (2015)

    Download PDF (610 KB) View Article

  6. Article

    Open Access

    Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors

    Background Atezolizumab is an engineered immunoglobulin monoclonal antibody that targets the programmed death-1/programmed death-ligand 1 pathway. Methods In this phase I dose-finding stu...

    Hidenori Mizugaki, Noboru Yamamoto, Haruyasu Murakami… in Investigational New Drugs (2016)

    Download PDF (381 KB) View Article